Publications by authors named "Satish Jetta"

Claim this Profile
D
Drug Development.
Ramakrishna Nirogi, Renny Abraham, Jyothsna Ravulu, Satish Jetta, Vijay Benade

Alzheimers Dement· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Ramakrishna Nirogi, Anil Shinde, Vinod Kumar Goyal, Jyothsna Ravula, Vijay Benade, Satish Jetta

Sleep Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects.
Ramakrishna Nirogi, Jyothsna Ravula, Vijay Benade, Vinod Kumar Goyal, Santosh Kumar Pandey, Satish Jetta

Cancer Chemother Pharmacol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study.
Ramakrishna Nirogi, Vinod Kumar Goyal, Vijay Benade, Ramkumar Subramanian, Jyothsna Ravula, Satish Jetta

Neurol Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses.
Ramakrishna Nirogi, Pradeep Jayarajan, Vijay Benade, Anil Shinde, Vinod Kumar Goyal, Satish Jetta

Int J Geriatr Psychiatry· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects.
Ramakrishna Nirogi, Vijay Benade, Vinod Kumar Goyal, Santosh Kumar Pandey, Abdul Rasheed Mohammed, Satish Jetta

Clin Drug Investig· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study.
Ramakrishna Nirogi, John Ieni, Vinod Kumar Goyal, Jyothsna Ravula, Satish Jetta

Alzheimers Dement (N Y)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.
Ramakrishna Nirogi, Gopinadh Bhyrapuneni, Nageswara Rao Muddana, Vinod Kumar Goyal, Santosh Kumar Pandey, Satish Jetta

Clin Drug Investig· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
Ramakrishna Nirogi, Koteshwara Mudigonda, Gopinadh Bhyrapuneni, Nageswara Rao Muddana, Anil Shinde, Satish Jetta

Clin Drug Investig· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis